Lenalidomide in multiple myeloma

References

• Sirohi B, Powles R. Multiple myeloma. Lancet363(9412), 875–887 (2004).
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.341(21), 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood100(9), 3063–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol.27(21), 3518–3525 (2009).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R, Mehta J et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant.36(1), 19–24 (2005).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R, Harousseau JL, Anderson KC. The evolving background for high-dose treatment for myeloma. Bone Marrow Transplant.40(12), 1097–1100 (2007).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood96(9), 2943–2950 (2000).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia22(7), 1343–1353 (2008).
   PubMed Web of Science ®Google Scholar
• Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin. Pharmacother.10(1), 125–133 (2009).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood108(10), 3458–3464 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin. Hematol.42(4 Suppl. 4), S3–S8 (2005).
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother.58(7), 1033–1045 (2009).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood100(9), 3063–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network. J. Clin. Oncol.25(28), 4459–4465 (2007).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet367(9513), 825–831 (2006).
   PubMed Web of Science ®Google Scholar
• Cavo M, Patriarca F, Tacchetti P et al. Bortezomib (Velcade®)–thalidomide–dexamethasone (VTD) vs thalidomide–dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts110(11), 73 (2007).
   Google Scholar
• Richardson P, Lonial S, Jakubowiak A et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I/II Study. ASH Annual Meeting Abstracts112(11), 92 (2008).
   Google Scholar
• Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med.357(21), 2133–2142 (2007).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med.357(21), 2123–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Wang M, Dimopoulos MA, Chen C et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood112(12), 4445–4451 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Schey SA, Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br. J. Haematol.137(3), 268–269 (2007).
   PubMed Web of Science ®Google Scholar
• Schey S, Morgan GJ, Ramasamy K et al. CRD: a Phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed/refractory myeloma. ASH Annual Meeting Abstracts112(11), 3707 (2008).
   Google Scholar
• Knop S, Gerecke C, Liebisch P et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood113(18), 4137–4143 (2009).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med.310(21), 1353–1356 (1984).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Avigan DE et al. Lenalidomide plus bortezomib (Rev–Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter Phase 1 trial. ASH Annual Meeting Abstracts108(11), 405 (2006).
   Google Scholar
• Richardson P, Jagannath S, Jakubowiak A et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a Phase II study. ASH Annual Meeting Abstracts112(11), 1742 (2008).
   Google Scholar
• Palumbo A, Falco P, Sanpaolo G et al. Combination of lenalidomide, melphalan, prednisone and thalidomide (RMPT) in relapsed/refractory multiple myeloma: results of a multicenter Phase II clinical trial. ASH Annual Meeting Abstracts112(11), 868 (2008).
   Google Scholar
• Baz R, Walker E, Karam MA et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol.17(12), 1766–1771 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106(13), 4050–4053 (2005).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander N et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts110(11), 74 (2007).
   Google Scholar
• Richardson P, Lonial S, Jakubowiak A et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I/II Study. ASH Annual Meeting Abstracts112(11), 92 (2008).
   Google Scholar
• Kumar S, Hayman S, Buadi F et al. Phase II trial of lenalidomide (Revlimid™) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. ASH Annual Meeting Abstracts112(11), 91 (2008).
   Google Scholar
• Kumar S, Flinn IW, Noga SJ et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the Phase I/II multi-center EVOLUTION study. ASH Annual Meeting Abstracts112(11), 93 (2008).
   Google Scholar
• Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood112(8), 3107–3114 (2008).
   PubMed Web of Science ®Google Scholar
• Roy V, Stewart AK, Bergsagel PL et al. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation. ASH Annual Meeting Abstracts112(11), 2769 (2008).
   Google Scholar
• Coleman M, Leonard J, Lyons L et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom’s macroglobulinemia. Leuk. Lymphoma43(9), 1777–1782 (2002).
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood111(3), 1101–1109 (2008).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Gay F et al. Bortezomib–doxorubicin–dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. ASH Annual Meeting Abstracts112(11), 159 (2008).
   Google Scholar
• Popat R, Oakervee HE, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br. J. Haematol.141(4), 512–516 (2008).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Rajkumar SV. Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized Phase III trial. Clin. Lymphoma Myeloma8(5), 315–317 (2008).
   PubMedGoogle Scholar
• Berenson JR, Crowley JJ, Grogan TM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood99(9), 3163–3168 (2002).
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol.27(11), 1788–1793 (2009).
   PubMed Web of Science ®Google Scholar
• Miguel JFS, Dimopoulos MA, Stadtmauer EA et al. Longer duration of treatment and maintenance of best response with lenalidomide and dexamethasone prolongs overall survival in patients with relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts112(11), 3702 (2008).
   Google Scholar
• Lehmann F, El-Cheikh J Jr, Zabelina T et al. Lenalidomide as salvage therapy after allogeneic stem cell transplantation in multiple myeloma. ASH Annual Meeting Abstracts112(11), 3704 (2008).
   Google Scholar
• Stadtmauer EA, Weber DM, Niesvizky R et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur. J. Haematol.82(6), 426–432 (2009).
   PubMed Web of Science ®Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia21(3), 529–534 (2007).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res.64(4), 1546–1558 (2004).
   PubMedGoogle Scholar
• Reece D, Song KW, Fu T et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood114(3), 522–525 (2009).
   PubMed Web of Science ®Google Scholar
• Dawson MA, Opat SS, Taouk Y et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin. Cancer Res.15(2), 714–722 (2009).
   PubMed Web of Science ®Google Scholar
• Schilling G, Hansen T, Shimoni A et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia22(6), 1250–1255 (2008).
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood114(3), 518–521 (2009).
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel JS, Durie BGM et al. International Staging System for multiple myeloma. J. Clin. Oncol.23(15), 3412–3420 (2005).
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia23(6), 1152–1157 (2009).
   PubMed Web of Science ®Google Scholar
• Shah SR, Tran TM. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs67(13), 1869–1881 (2007).
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Naib T, Christos PJ et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Haematol.138(5), 640–643 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobus S, Kumar S, Callander NS et al. Effect of venous thrombotic events on overall survival in multiple myeloma: analysis of thrombotic events occurring in E4A03A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG). ASH Annual Meeting Abstracts112(11), 1740 (2008).
   Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia22(2), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb. Res.123(5), 679–686 (2009).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R, Mehta J et al. The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med. Oncol.18(1), 39–50 (2001).
   PubMed Web of Science ®Google Scholar
• Schoenland SO, Bochtler T, Dietrich S et al. Single center experience of lenalidomide/dexamethasone treatment in 40 patients with light chain amyloidosis: high toxicity in patients with severe impaired renal and cardiac function. ASH Annual Meeting Abstracts112(11), 1736 (2008).
   Google Scholar
• White DJ, Bahlis NJ, Marcellus DC et al. Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: the NCIC CTG MY.11 trial. ASH Annual Meeting Abstracts112(11), 2767 (2008).
   Google Scholar
• Palumbo A, Falco P, Gay F et al. Oral melphalan, prednisone, and lenalidomide for newly diagnosed multiple myeloma patients: kinetics of neutropenia/thrombocytopenia and time to event results. ASH Annual Meeting Abstracts112(11), 2768 (2008).
   Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia21(9), 2035–2042 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar S, Lacy M, Dispenzieri A et al. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts112(11), 3467 (2008).
   Google Scholar
• Kumar S, Giralt S, Stadtmauer EA et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood114(9), 1729–1735 (2009).
   PubMed Web of Science ®Google Scholar
• Paripati H, Stewart AK, Cabou S et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia22(6), 1282–1284 (2008).
   PubMed Web of Science ®Google Scholar
• Giralt S, Stadtmauer EA, Harousseau JL et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia23(10), 1904–1912 (2009).
   PubMed Web of Science ®Google Scholar
• Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. DOI: 10.1038/bmt.2009.130 (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur. J. Cancer42(11), 1671–1683 (2006).
   PubMed Web of Science ®Google Scholar
• Deniz B, Morgan G, Schey S et al. Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK. ASH Annual Meeting Abstracts112(11), 2400 (2008).
   Google Scholar
• Schey SA, Fields P, Bartlett JB et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol.22(16), 3269–3276 (2004).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. ASH Annual Meeting Abstracts112(11), 866 (2008).
   Google Scholar
• Chauhan D, Singh AV, Brahmandam M et al. Combination of a novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vivo synergistic cytotoxicity in multiple myeloma. ASH Annual Meeting Abstracts112(11), 3662 (2008).
   Google Scholar
• Siegel D, Weber D, Mitsiades CS et al. A Phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts112(11), 3705 (2008).
   Google Scholar
• Jakubowiak A, Zimmerman T, Alsina M et al. A Multiple Myeloma Research Consortium (MMRC) multicenter Phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM): updated results. ASH Annual Meeting Abstracts110(11), 1169 (2007).
   Google Scholar
• Jakubowiak A, Richardson P, Zimmerman TM et al. Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). ASH Annual Meeting Abstracts112(11), 3691 (2008).
   Google Scholar
• Reece DE, Masih-Khan E, Khan A et al. Phase I–II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid®) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma. ASH Annual Meeting Abstracts112(11), 1723 (2008).
   Google Scholar